How should I diagnose and manage a patient with suspected community‑acquired pneumonia?

Diagnosing and Managing Community-Acquired Pneumonia

Diagnose CAP based on clinical signs/symptoms (cough, fever, dyspnea, pleuritic chest pain) plus chest X-ray confirmation showing new infiltrate, then immediately initiate empiric antibiotics without waiting for microbiological results. 1, 2

Initial Diagnostic Approach

Clinical Presentation

• Look for at least two of the following: temperature >38°C or ≤36°C, new or increased cough, dyspnea, pleuritic chest pain, leukocyte count <4,000/μL or >10,000/μL 3
• Assess for rigors, fatigue, and signs of respiratory distress 4
• Do not rely on clinical characteristics alone to determine bacterial versus atypical etiology—this distinction has limited clinical value and cannot be made reliably 1

Radiographic Confirmation

• Chest X-ray is the standard for confirming pneumonia and should show air space consolidation or new infiltrate 1, 3
• Clinical diagnosis alone is acceptable in mild outpatient cases where chest X-ray is not immediately available 1
• Lung ultrasound is increasingly recognized as a more sensitive alternative, though not yet standard practice 2

Severity Assessment (Determines All Subsequent Management)

• Use PSI (Pneumonia Severity Index) or CURB-65 score immediately to determine hospitalization need 1, 5
• CURB-65 ≥2 mandates hospital admission 6
• Severe CAP criteria requiring ICU admission: septic shock requiring vasopressors OR respiratory failure requiring mechanical ventilation OR ≥3 minor criteria (confusion, RR ≥30/min, SBP <90 mmHg, multilobar infiltrates, PaO₂/FiO₂ <250) 1, 6

Microbiological Testing Strategy

Outpatient Setting

• Do NOT obtain routine sputum cultures, blood cultures, or urine antigen testing in outpatients 1, 5
• Test for COVID-19 and influenza when these viruses are circulating in the community, as positive results affect treatment and infection control 3
• Reserve microbiological testing for treatment failures or public health concerns (e.g., suspected Legionella outbreak) 1

Hospitalized Non-Severe CAP

• Obtain two sets of blood cultures from separate sites before first antibiotic dose 6
• Sputum Gram stain and culture only if high-quality specimen can be rapidly processed 5
• Do not delay antibiotics while waiting for sputum collection 5

Severe CAP (ICU Patients)

• Mandatory pretreatment testing: blood cultures (two sets), sputum Gram stain and culture, urine antigens for pneumococcus and Legionella 1, 5
• These tests enable pathogen-directed therapy and safe de-escalation 6

Critical Pitfall

• Up to 50% of CAP patients will have no pathogen identified even with extensive testing—this should not delay or alter initial empiric therapy 1, 7
• Of those with identified pathogens, only 15% have Streptococcus pneumoniae, and up to 40% have viral etiologies 3

Empiric Antibiotic Selection

Outpatient Without Comorbidities

• First-line: Amoxicillin 1 g orally three times daily for 5-7 days 6
• Alternative if amoxicillin intolerant: Doxycycline 100 mg orally twice daily 6
• Avoid macrolide monotherapy unless local pneumococcal macrolide resistance is documented <25% 6

Outpatient With Comorbidities

• Amoxicillin/clavulanate or cephalosporin plus macrolide 5
• Comorbidities include chronic heart, lung, liver, or renal disease; diabetes; alcoholism; malignancy; asplenia 4

Hospitalized Non-ICU

• Preferred regimen: Ceftriaxone 1-2 g IV once daily PLUS azithromycin 500 mg daily 6, 3
• Alternative β-lactams: cefotaxime 1-2 g IV every 8 hours or ampicillin-sulbactam 3 g IV every 6 hours, always combined with macrolide 6
• Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) is equally effective 6
• Never use macrolide monotherapy in hospitalized patients—provides inadequate coverage for typical bacterial pathogens 6

Severe CAP (ICU)

• Mandatory combination therapy: Ceftriaxone 2 g IV once daily PLUS azithromycin 500 mg IV daily (or respiratory fluoroquinolone) 6, 3
• Monotherapy is inadequate and associated with higher mortality in critically ill patients 6
• Combination therapy specifically reduces mortality in bacteremic pneumococcal pneumonia 6

Special Populations Requiring Modified Coverage

Add MRSA coverage (vancomycin 15 mg/kg IV every 8-12 hours or linezolid 600 mg IV every 12 hours) if: 6

• Prior MRSA infection or colonization
• Recent hospitalization with IV antibiotics within 90 days
• Post-influenza pneumonia
• Cavitary infiltrates on imaging

Add antipseudomonal coverage (piperacillin-tazobactam or cefepime or meropenem) if: 6

• Structural lung disease (bronchiectasis)
• Prior respiratory isolation of Pseudomonas aeruginosa
• Recent hospitalization with IV antibiotics within 90 days
• Repeated severe COPD exacerbations with frequent steroid/antibiotic use

Antibiotic Timing

• Administer first antibiotic dose within 1 hour of diagnosis in the emergency department 6
• Delays beyond 8 hours increase 30-day mortality by 20-30% 6
• Never delay antibiotics to obtain diagnostic specimens—obtain cultures then immediately start therapy 5

Treatment Duration

• Minimum 5 days of therapy for all patients 1, 6
• Continue until afebrile for 48-72 hours with no more than one sign of clinical instability 6
• Clinical stability criteria: temperature ≤37.8°C, heart rate ≤100 bpm, respiratory rate ≤24/min, SBP ≥90 mmHg, SpO₂ ≥90% on room air, able to maintain oral intake, normal mental status 6
• Typical duration for uncomplicated CAP is 5-7 days 6, 3
• Extended duration (14-21 days) required for Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli 6

Transition from IV to Oral Therapy

• Switch when patient is hemodynamically stable, clinically improving, able to take oral medications, and has normal GI function—typically by hospital day 2-3 6, 4
• Specific criteria: SBP ≥90 mmHg, HR ≤100 bpm, afebrile 48-72 hours, RR ≤24/min, SpO₂ ≥90% on room air 6
• Oral step-down options: amoxicillin 1 g three times daily plus azithromycin 500 mg daily, or transition to respiratory fluoroquinolone 6

Adjunctive Corticosteroid Therapy

• Consider systemic corticosteroids within 24 hours of development of severe CAP to reduce 28-day mortality 3
• Do not routinely use corticosteroids except in refractory septic shock or severe CAP 1
• Not indicated for non-severe CAP 5

Follow-Up and Monitoring

• Do not obtain routine follow-up chest radiographs in patients who achieve clinical stability 1
• Consider lung cancer screening if patient meets eligibility criteria (age 50-80 years, 20 pack-year smoking history) 1
• Persistent symptoms or failure to improve by day 3 warrants reassessment and consideration of alternative diagnoses or resistant pathogens 1

Key Pitfalls to Avoid

• Never delay antibiotics for diagnostic testing—empiric therapy must begin immediately 5
• Do not use sputum Gram stain alone to guide initial therapy 5
• Avoid macrolide monotherapy in hospitalized patients or areas with pneumococcal macrolide resistance >25% 6
• Do not use indiscriminate fluoroquinolones in uncomplicated outpatient CAP due to FDA warnings about serious adverse events 6
• Remember that clinical presentation cannot reliably distinguish typical from atypical pathogens—use empiric regimens that cover both 1